Tempest Q2 net loss $5.2M; TPST-4003 collaboration with Senlang, first dosing Q4 2026

Tempest Therapeutics, Inc.

Q2 net loss $5.2M ($0.34/share) vs $7.9M ($2.07) year ago; cash $0.8M at June 30.
Collaboration with Senlang Biotechnology for TPST-4003 in vivo CAR-T; first dosing expected Q4 2026, data H1 2027.
TPST-2003 trials: 100% complete response in 15 CAR-T-naive evaluable patients; no Grade ≥3 CRS/ICANS.
Appointed Drake Richey and John Yee to board; Andrew Fang as Head of Business Development.
Warrant inducement raised ~$2M gross proceeds; H1 cash used in ops $10.4M.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.